|
1
|
Nussinov R, Tsai CJ and Jang H: Anticancer
drug resistance: An update and perspective. Drug Resist Updat.
59:1007962021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zilla MK, Nayak D, Amin H, Nalli Y, Rah B,
Chakraborty S, Kitchlu S, Goswami A and Ali A:
4′-Demethyl-deoxypodophyllotoxin glucoside isolated from
Podophyllum hexandrum exhibits potential anticancer activities by
altering Chk-2 signaling pathway in MCF-7 breast cancer cells. Chem
Biol Interact. 224:100–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martău GA, Bernadette-Emőke T, Odocheanu
R, Soporan DA, Bochiș M, Simon E and Vodnar DC: Vaccinium species
(Ericaceae): Phytochemistry and biological properties of medicinal
plants. Molecules. 28:15332023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruan J, Shi Z, Cao X, Dang Z, Zhang Q,
Zhang W, Wu L, Zhang Y and Wang T: Research progress on
anti-inflammatory effects and related mechanisms of astragalin. Int
J Mol Sci. 25:44762024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barge S, Deka B, Kashyap B, Bharadwaj S,
Kandimalla R, Ghosh A, Dutta PP, Samanta SK, Manna P, Borah JC and
Talukdar NC: Astragalin mediates the pharmacological effects of
Lysimachia candida Lindl on adipogenesis via downregulating PPARG
and FKBP51 signaling cascade. Phytother Res. 35:6990–7003. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mladenova SG, Vasileva LV, Savova MS,
Marchev AS, Tews D, Wabitsch M, Ferrante C, Orlando G and Georgiev
MI: Anti-Adipogenic effect of alchemilla monticola is mediated Via
PI3K/AKT signaling inhibition in human adipocytes. Front Pharmacol.
12:7075072021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ceramella J, Loizzo MR, Iacopetta D,
Bonesi M, Sicari V, Pellicanò TM, Saturnino C, Malzert-Fréon A,
Tundis R, Sinicropi MS, et al: Anchusa azurea Mill. (Boraginaceae)
aerial parts methanol extract interfering with cytoskeleton
organization induces programmed cancer cells death. Food Funct.
10:4280–4290. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J, Zhong K, Qin S, Jing Y, Liu S, Li
D and Peng C: Astragalin: A food-origin flavonoid with therapeutic
effect for multiple diseases. Front Pharmacol. 14:12659602023.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tao Y, Bao J, Zhu F, Pan M, Liu Q and Wang
P: Ethnopharmacology of Rubus idaeus Linnaeus: A critical review on
ethnobotany, processing methods, phytochemicals, pharmacology and
quality control. J Ethnopharmacol. 302:1158702023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao ZW, Zhang M, Wang G, Zou J, Gao JH,
Zhou L, Wan XJ, Zhang DW, Yu XH and Tang CK: Astragalin retards
atherosclerosis by promoting cholesterol efflux and inhibiting the
inflammatory response via upregulating ABCA1 and ABCG1 expression
in macrophages. J Cardiovasc Pharmacol. 77:217–227. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rajani V, Umadevi S and Raju CN: A review
on exploring the phytochemical and pharmacological significance of
Indigofera astragalina. Pharmacogn Mag. 20:363–371. 2024.
View Article : Google Scholar
|
|
12
|
Wang N, Singh D and Wu Q: Astragalin
attenuates diabetic cataracts via inhibiting aldose reductase
activity in rats. Int J Ophthalmol. 16:1186–1195. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bangar SP, Singh A, Chaudhary V, Sharma N
and Lorenzo JM: Beetroot as a novel ingredient for its versatile
food applications. Crit Rev Food Sci Nutr. 63:8403–8427. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mohammed AE, Alghamdi SS, Shami A, Suliman
RS, Aabed K, Alotaibi MO and Rahman I: In silico prediction of
malvaviscus arboreus metabolites and green synthesis of silver
nanoparticles-opportunities for safer anti-bacterial and
anti-cancer precision medicine. Int J Nanomedicine. 18:2141–2162.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen SC, Xiang XY, Han WC, Chen MY and Xie
BC: Research progress on pharmacological properties and mechanism
of astragalin. Chin J Tradit Chin Med. 40:118–123+287. 2022.(In
Chinese).
|
|
16
|
Yang M, Li WY, Xie J, Wang ZL, Wen YL,
Zhao CC, Tao L, Li LF, Tian Y and Sheng J: Astragalin inhibits the
proliferation and migration of human colon cancer HCT116 cells by
regulating the NF-κB signaling pathway. Front Pharmacol.
12:6392562021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Lv J, Li X and Lin Q: The
flavonoid Astragalin shows anti-tumor activity and inhibits
PI3K/AKT signaling in gastric cancer. Chem Biol Drug Des.
98:779–786. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian S, Wei Y, Hu H and Zhao H: Mixed
computational-experimental study to reveal the anti-metastasis and
anti-angiogenesis effects of Astragalin in human breast cancer.
Comput Biol Med. 150:1061312022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sharma R: Mapping of global, regional and
national incidence, mortality and mortality-to-incidence ratio of
lung cancer in 2020 and 2050. Int J Clin Oncol. 27:665–675. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rossi R, De Angelis ML, Xhelili E, Sette
G, Eramo A, De Maria R, Incani UC, Francescangeli F and Zeuner A:
Lung cancer organoids: The rough path to personalized medicine.
Cancers (Basel). 14:37032022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prete M, Ballarin G, Porciello G, Arianna
A, Luongo A, Belli V, Scalfi L and Celentano E: Bioelectrical
impedance analysis-derived phase angle (PhA) in lung cancer
patients: A systematic review. BMC Cancer. 24:6082024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu S, Wei W, Wang J and Chen T:
Theranostic applications of selenium nanomedicines against lung
cancer. J Nanobiotechnology. 21:962023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xi Chen and Jin Qi: Flavonoids and
Alkaloids in Lotus Leaves. Chin J Exp Tradit Med Formulae. 211–214.
2015.
|
|
24
|
Wang D, Yu J, Cheng L, Hu X, Xiang M, Zhou
Y, Tao B, Liu C and Xia Y: Research Progress on Main Constituents
and Biological Activities of Lotus Leaves. Agricultural Technology
& Equipment. 71–72. 742021.(In Chinese).
|
|
25
|
Jia XB, Zhang Q, Xu L, Yao WJ and Wei L:
Lotus leaf flavonoids induce apoptosis of human lung cancer A549
cells through the ROS/p38 MAPK pathway. Biol Res. 54:72021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu G, Yu B, Wang R, Jiang J, Wen F and Shi
X: Astragalin flavonoid inhibits proliferation in human lung
carcinoma cells mediated via induction of caspase-dependent
intrinsic pathway, ROS production, cell migration and invasion
inhibition and targeting JAK/STAT signalling pathway. Cell Mol Biol
(Noisy-le-grand). 67:44–49. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao D, Bai JC and Zhang B: Research
progress of signal pathways related to the anti-tumor effect of
Astragalin. J Pract Oncol. 38:62–66. 2024.
|
|
28
|
Liang Y and Chen W: Effect of Astragalin
on proliferation, migration, apoptosis and oxidative stress of lung
cancer A549 cells. Chin J Clin Pharmacol. 39:999–1003. 2023.(In
Chinese).
|
|
29
|
Chen M, Cai F, Zha D, Wang X, Zhang W, He
Y, Huang Q, Zhuang H and Hua ZC: Astragalin-induced cell death is
caspase-dependent and enhances the susceptibility of lung cancer
cells to tumor necrosis factor by inhibiting the NF-кB pathway.
Oncotarget. 8:26941–26958. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yan C, Pang X, Fan W, Dai W, Hu X, Mei Q
and Zeng C: Mechanism of leaves of Microcos paniculata
improving of dyspepsia based on network pharmacology and molecular
docking. Drugs & Clinic. 38:1335–1343. 2023.(In Chinese).
|
|
31
|
Li M, Zhao Z, Xuan J, Li Z and Ma T:
Advances in Studies on Chemical Constituents and Pharmacological
Effects of Lotus Leaves. Journal of Liaoning University of TCM.
22:135–138. 2020.(In Chinese).
|
|
32
|
Bai J, Chen Y, Zhao G and Gui R: In vitro
and vivo experiments revealing astragalin inhibited lung
adenocarcinoma development via LINC00582/miR-140-3P/PDPK1. J
Biochem Mol Toxicol. 38:e700422024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ribeiro V, Ferreres F, Macedo T,
Gil-Izquierdo Á, Oliveira AP, Gomes NGM, Araújo L, Pereira DM,
Andrade PB and Valentão P: Activation of caspase-3 in gastric
adenocarcinoma AGS cells by Xylopia aethiopica (Dunal) A. Rich.
fruit and characterization of its phenolic fingerprint by
HPLC-DAD-ESI(Ion Trap)-MSn and UPLC-ESI-QTOF-MS2. Food Res Int.
141:1101212021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
35
|
Webb PM and Jordan SJ: Global epidemiology
of epithelial ovarian cancer. Nat Rev Clin Oncol. 21:389–400. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G
and Jin WL: Immunotherapy for ovarian cancer: Adjuvant,
combination, and neoadjuvant. Front Immunol. 11:5778692020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gu L, Du N, Jin Q, Li S, Xie L, Mo J, Shen
Z, Mao D, Ji J, et al: Magnitude of benefit of the addition of poly
ADP-ribose polymerase (PARP) inhibitors to therapy for malignant
tumor: A meta-analysis. Crit Rev Oncol Hematol. 147:1028882020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song L and Fu Q: Study of the effect of
astragalin on proliferation of ovarian cancer cells by inhibiting
the glycolytic pathway induced Via HIF-1α. Pract Oncol J.
32:503–509. 2018.
|
|
39
|
Ling Song and Qiong Fu: Astragalin
inhibits hypoxia-induced proliferation and invasion of ovarian
cancer cells by up-regulating PHD2. J Pract Oncol. 33:407–414.
2019.
|
|
40
|
Mazzone M, Dettori D, de Oliveira RL,
Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, de
Almodovar CR, et al: Heterozygous deficiency of PHD2 restores tumor
oxygenation and inhibits metastasis via endothelial normalization.
Cell. 136:839–851. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guentsch A, Beneke A, Swain L, Farhat K,
Nagarajan S, Wielockx B, Raithatha K, Dudek J, Rehling P and
Zieseniss A: PHD2 is a regulator for glycolytic reprogramming in
macrophages. Mol Cell Biol. 37:e00236–e00216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mehla K and Singh PK: MUC1: A novel
metabolic master regulator. Biochim Biophys Acta. 1845:126–135.
2014.PubMed/NCBI
|
|
43
|
Katayama Y, Uchino J, Chihara Y, Tamiya N,
Kaneko Y, Yamada T and Takayama K: Tumor neovascularization and
developments in therapeutics. Cancers (Basel). 11:3162019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li RL, He LY, Zhang Q, Liu J, Lu F, Duan
HX, Fan LH, Peng W, Huang YL and Wu CJ: HIF-1α is a potential
molecular target for herbal medicine to treat diseases. Drug Des
Devel Ther. 14:4915–4949. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang CZ, Wang SH, Zhang RH, Lin JH, Tian
YH, Yang YQ, Liu J and Ma YX: Neuroprotective effect of astragalin
via activating PI3K/Akt-mTOR-mediated autophagy on APP/PS1 mice.
Cell Death Discov. 9:152023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:
Biological and therapeutic significance. Semin Cancer Biol.
59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shu-ping Qu, Chun-jun Liu and Ju-hua
Liang: Correlation between serum miR-410,miR-875 expression with
HPV infection in cervical cancer patients. J Path Biol.
19:1404–1407. 2024.
|
|
48
|
Abu-Rustum NR, Yashar CM, Arend R, Barber
E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA,
et al: NCCN Guidelines® insights: Cervical cancer,
version 1.2024. J Natl Compr Canc Netw. 21:1224–1233. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Raj S, Prasad RR and Ranjan A: Incidence
of vaginal toxicities following definitive chemoradiation in intact
cervical cancer: A meta-analysis. J Contemp Brachytherapy.
16:241–256. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zeng W and Chen L: Astragalin inhibits the
proliferation of high-risk HPV-positive cervical epithelial cells
and attenuates malignant cervical lesions. Cytotechnology.
77:802025. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
He M, Yasin K, Yu S, Li J and Xia L: Total
flavonoids in Artemisia absinthium L. and evaluation of its
anticancer activity. Int J Mol Sci. 24:163482023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zerrouki S, Mezhoud S, Yilmaz MA,
Yaglioglu AS, Bakir D, Demirtas I and Mekkiou R: LC/MS-MS analyses
and in vitro anticancer activity of Tourneuxia variifolia
extracts. Nat Prod Res. 36:4506–4510. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xu X, Zhou N, Lan H, Yang F, Dong B and
Zhang X: The ferroptosis molecular subtype reveals characteristics
of the tumor microenvironment, immunotherapeutic response, and
prognosis in gastric cancer. Int J Mol Sci. 23:97672022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mamun TI, Younus S and Rahman MH: Gastric
cancer-Epidemiology, modifiable and non-modifiable risk factors,
challenges and opportunities: An updated review. Cancer Treat Res
Commun. 41:1008452024.PubMed/NCBI
|
|
56
|
Wang J, Du L and Chen X: Adenosine
signaling: Optimal target for gastric cancer immunotherapy. Front
Immunol. 13:10278382022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu Y, Huang T, Wang L, Wang Y, Liu Y, Bai
J, Wen X, Li Y, Long K and Zhang H: Traditional Chinese medicine in
the treatment of chronic atrophic gastritis, precancerous lesions
and gastric cancer. J Ethnopharmacol. 337:1188122025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Radziejewska I, Supruniuk K, Tomczyk M,
Izdebska W, Borzym-Kluczyk M, Bielawska A, Bielawski K and Galicka
A: p-Coumaric acid, Kaempferol, Astragalin and Tiliroside influence
the expression of glycoforms in AGS gastric cancer cells. Int J Mol
Sci. 23:86022022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chu ZH, He SY, Wang Y, Zhu RT, Gu YL and
Chen JY: Effects of Astragalin on apoptosis of undifferentiated
gastric cancer cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi.
38:520–524. 2022.(In Chinese). PubMed/NCBI
|
|
60
|
Sharafutdinov I, Tegtmeyer N, Linz B,
Rohde M, Vieth M, Tay AC, Lamichhane B, Tuan VP, Fauzia KA, Sticht
H, et al: A single-nucleotide polymorphism in Helicobacter pylori
promotes gastric cancer development. Cell Host Microbe.
31:1345–1358.e6. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tan A, Scortecci KC, De Medeiros NM,
Kukula-Koch W, Butler TJ, Smith SM and Boylan F: Plukenetia
volubilis leaves as source of anti-Helicobacter pylori agents.
Front Pharmacol. 15:14614472024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Murphy CC and Zaki TA: Changing
epidemiology of colorectal cancer-birth cohort effects and emerging
risk factors. Nat Rev Gastroenterol Hepatol. 21:25–34. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ebnudesita FR, Dienanta SB, Jannah AR and
I'tishom R: Potency of soursop leaf extract and curcumin with
magnetic and mucus-penetrating nanoparticle as colorectal cancer
alternative therapY. J Vocational Health Studies. 5:186–191. 2022.
View Article : Google Scholar
|
|
64
|
Abedizadeh R, Majidi F, Khorasani HR,
Abedi H and Sabour D: Colorectal cancer: A comprehensive review of
carcinogenesis, diagnosis, and novel strategies for classified
treatments. Cancer Metastasis Rev. 43:729–753. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chen L, Chen C, Wang P and Song T:
Mechanisms of cellular effects directly induced by magnetic
nanoparticles under magnetic fields. J Nanomaterials. 2017:1–13.
2017. View Article : Google Scholar
|
|
66
|
Eng C, Yoshino T, Ruíz-García E, Mostafa
N, Cann CG, O'Brian B, Benny A, Perez RO and Cremolini C:
Colorectal cancer. Lancet. 404:294–310. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zou Y, Wang S, Zhang H, Gu Y, Chen H,
Huang Z, Yang F, Li W, Chen C, Men L, et al: The triangular
relationship between traditional Chinese medicines, intestinal
flora, and colorectal cancer. Med Res Rev. 44:539–567. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Augustynowicz D, Lemieszek MK, Strawa JW,
Wiater A and Tomczyk M: Anticancer potential of acetone extracts
from selected Potentilla species against human colorectal cancer
cells. Front Pharmacol. 13:10273152022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhai Y, Sun J, Sun C, Zhao H, Li X, Yao J,
Su J, Xu X, Xu X, Hu J, et al: Total flavonoids from the dried root
of Tetrastigma hemsleyanum Diels et Gilg inhibit colorectal cancer
growth through PI3K/AKT/mTOR signaling pathway. Phytother Res.
36:4263–4277. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Tragulpakseerojn J, Yamaguchi N,
Pamonsinlapatham P, Wetwitayaklung P, Yoneyama T, Ishikawa N,
Ishibashi M and Apirakaramwong A: Anti-proliferative effect of
Moringa oleifera Lam (Moringaceae) leaf extract on human colon
cancer HCT116 cell line. Trop J Pharm Res. 16:371–378. 2017.
View Article : Google Scholar
|
|
71
|
Chidambaram A, Prabhakaran R, Sivasamy S,
Kanagasabai T, Thekkumalai M, Singh A, Tyagi MS and Dhandayuthapani
S: Male breast cancer: Current scenario and future perspectives.
Technol Cancer Res Treat. 23:153303382412618362024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Palmer BV, Walsh GA, McKinna JA and
Greening WP: Adjuvant chemotherapy for breast cancer: Side effects
and quality of life. BMJ. 281:1594–1597. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Di Nardo P, Lisanti C, Garutti M, Buriolla
S, Alberti M, Mazzeo R and Puglisi F: Chemotherapy in patients with
early breast cancer: Clinical overview and management of long-term
side effects. Expert Opin Drug Saf. 21:1341–1355. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kim SD, Kwag EB, Yang MX and Yoo HS:
Efficacy and safety of ginger on the side effects of chemotherapy
in breast cancer patients: systematic review and meta-analysis. Int
J Mol Sci. 23:112672022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Peeters NJMC, Kaplan ZLR, Clarijs ME,
Mureau MAM, Verhoef C, van Dalen T, Husson O and Koppert LB:
Health-related quality of life (HRQoL) after different axillary
treatments in women with breast cancer: A 1-year longitudinal
cohort study. Qual Life Res. 33:467–479. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Meng X, Zhang A, Wang X and Sun H: A
kaempferol-3-O-β-D-glucoside, intervention effect of astragalin on
estradiol metabolism. Steroids. 149:1084132019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zeb A, Khan W, Ul Islam W, Khan F, Khan A,
Khan H, Khalid A, Rehman NU, Ullah A and Al-Harrasi A: Exploring
the anticancer potential of astragalin in triple negative breast
cancer cells by attenuating glycolytic pathway through AMPK/mTOR.
Curr Med Chem. Jul 25–2024.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nunnery SE and Mayer IA: Targeting the
PI3K/AKT/mTOR pathway in hormone-positive breast cancer. Drugs.
80:1685–1697. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Song X, Shen L, Contreras JM, Liu Z, Ma K,
Ma B, Liu X and Wang DO: New potential selective estrogen receptor
modulators in traditional Chinese medicine for treating menopausal
syndrome. Phytother Res. 38:4736–4756. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Huq AM, Stanslas J, Nizhum N, Uddin MN,
Maulidiani M, Roney M, Abas F and Jamal JA: Estrogenic
post-menopausal anti-osteoporotic mechanism of Achyranthes aspera
L.: Phytochemicals and network pharmacology approaches. Heliyon.
10:e387922024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bellai A, Deka S, Tag H, Bhattacharya K
and Hui PK: Integrated pharmacognostic and computational analysis
of Hydrocotyle javanica thunb. Phytochemicals as a potential
HER2 tyrosine kinase inhibitor in breast cancer. Pept Sci.
119:e243722024. View Article : Google Scholar
|
|
82
|
Ahn S, Jung H, Jung Y, Lee J, Shin SY, Lim
Y and Lee Y: Identification of the active components inhibiting the
expression of matrix metallopeptidase-9 by TNFα in ethyl acetate
extract of Euphorbia humifusa Willd. J Appl Biol Chem. 62:367–374.
2019. View Article : Google Scholar
|
|
83
|
Shin SY, Kim CG, Jung YJ, Jung Y, Jung H,
Im J, Lim Y and Lee YH: Euphorbia humifusa Willd exerts inhibition
of breast cancer cell invasion and metastasis through inhibition of
TNFα-induced MMP-9 expression. BMC Complement Altern Med.
16:4132016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cirillo L, Innocenti S and Becherucci F:
Global epidemiology of kidney cancer. Nephrol Dial Transplant.
39:920–928. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Young M, Jackson-Spence F, Beltran L, Day
E, Suarez C, Bex A, Powles T and Szabados B: Renal cell carcinoma.
Lancet. 404:476–491. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Imamura R, Tanaka R, Taniguchi A, Nakazawa
S, Kato T, Yamanaka K, Namba-Hamano T, Kakuta Y, Abe T, Tsutahara
K, et al: Everolimus reduces cancer incidence and improves patient
and graft survival rates after kidney transplantation: A
multi-center study. J Clin Med. 11:2492022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Chen H: microRNA-Based cancer diagnosis
and therapy. Int J Mol Sci. 25:2302024. View Article : Google Scholar
|
|
88
|
Zhang W, Chan C, Zhang K, Qin H, Yu BY,
Xue Z, Zheng X and Tian J: Discovering a new drug against acute
kidney injury by using a tailored photoacoustic imaging probe. Adv
Mater. 36:e23113972024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhu L, Zhu L, Chen J, Cui T and Liao W:
Astragalin induced selective kidney cancer cell death and these
effects are mediated via mitochondrial mediated cell apoptosis,
cell cycle arrest, and modulation of key tumor-suppressive miRNAs.
J BUON. 24:1245–1251. 2019.PubMed/NCBI
|
|
90
|
Wu N, Li J and Tao J: Hot spots in
diagnosis of malignant melanoma. J Diagn Concepts Pract.
22:215–219. 2023.(In Chinese).
|
|
91
|
Arnold M, Singh D, Laversanne M, Vignat J,
Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC and Bray
F: Global burden of cutaneous melanoma in 2020 and projections to
2040. JAMA Dermatol. 158:495–503. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Swetter SM, Johnson D, Albertini MR,
Barker CA, Bateni S, Baumgartner J, Bhatia S, Bichakjian C, Boland
G, Chandra S, et al: NCCN Guidelines® insights:
Melanoma: Cutaneous, version 2.2024: Featured updates to the NCCN
guidelines. J Natl Compr Canc Netw. 22:290–298. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ernst M and Giubellino A: The current
state of treatment and future directions in cutaneous malignant
melanoma. Biomedicines. 10:8222022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li J, Liu X, Wang W, Li C and Li X: MSK1
promotes cell proliferation and metastasis in uveal melanoma by
phosphorylating CREB. Arch Med Sci. 16:1176–1188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Li N, Zhang K, Mu X, Tian Q, Liu W, Gao T,
Ma X and Zhang J: Astragalin attenuates UVB radiation-induced
actinic keratosis formation. Anticancer Agents Med Chem.
18:1001–1008. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
You OH, Shin EA, Lee H, Kim JH, Sim DY,
Kim JH, Kim Y, Khil JH, Baek NI and Kim SH: Apoptotic effect of
astragalin in melanoma skin cancers via activation of caspases and
inhibition of sry-related HMg-Box gene 10. Phytother Res.
31:1614–1620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang J, Bian Y, Cheng Y, Sun R and Li G:
Effect of lemon peel flavonoids on UVB-induced skin damage in mice.
RSC Adv. 10:31470–31478. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Løvf M, Zhao S, Axcrona U, Johannessen B,
Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK,
et al: multifocal primary prostate cancer exhibits high degree of
genomic heterogeneity. Eur Urol. 75:498–505. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Lafontaine ML and Kokorovic A:
Cardiometabolic side effects of androgen deprivation therapy in
prostate cancer. Curr Opin Support Palliat Care. 16:216–222. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Moses KA, Sprenkle PC, Bahler C, Box G,
Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF,
et al: NCCN Guidelines® insights: Prostate cancer early
detection, version 1.2023. J Natl Compr Canc Netw. 21:236–246.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Beer TM, Hotte SJ, Saad F, Alekseev B,
Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, et al:
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus
cabazitaxel and prednisone alone in patients with metastatic
castration-resistant prostate cancer previously treated with
docetaxel (AFFINITY): A randomised, open-label, international,
phase 3 trial. Lancet Oncol. 18:1532–1542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Shahab MRF and Shahab N: Recent advances
and future directions in the management of metastatic
castration-resistant prostate cancer asing androgen receptor
signaling inhibitors and poly-adipose polymerase inhibitors: A
literature review. International J Multidisciplinary Research.
6:22024.
|
|
103
|
Koyuncu I, Temiz E, Seker F, Balos MM,
Akkafa F, Yuksekdag O, Yılmaz MA and Zengin G: A mixed-apoptotic
effect of Jurinea mesopotamica extract on prostate cancer cells: A
promising source for natural chemotherapeutics. Chem Biodivers.
21:e2023017472024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Kim H, Hwang B, Cho S, Kim WJ, Myung SC,
Choi YH, Kim WJ, Lee S and Moon SK: The ethanol extract of Cyperus
exaltatus var. iwasakii exhibits cell cycle dysregulation,
ERK1/2/p38 MAPK/AKT phosphorylation, and reduced MMP-9-mediated
metastatic capacity in prostate cancer models in vitro and in vivo.
Phytomedicine. 114:1547942023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li X, Ramadori P, Pfister D, Seehawer M,
Zender L and Heikenwalder M: The immunological and metabolic
landscape in primary and metastatic liver cancer. Nat Rev Cancer.
21:541–557. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li
JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, et al: Sequential
transarterial chemoembolisation and stereotactic body radiotherapy
followed by immunotherapy as conversion therapy for patients with
locally advanced, unresectable hepatocellular carcinoma
(START-FIT): A single-arm, phase 2 trial. Lancet Gastroenterol
Hepatol. 8:169–178. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Pennington B, Akehurst R, Wasan H, Sangro
B, Kennedy AS, Sennfält K and Bester L: Cost-effectiveness of
selective internal radiation therapy using yttrium-90 resin
microspheres in treating patients with inoperable colorectal liver
metastases in the UK. J Med Econ. 18:797–804. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Chen C, Chen F, Gu L, Jiang Y, Cai Z, Zhao
Y, Chen L, Zhu Z and Liu X: Discovery and validation of COX2 as a
target of flavonoids in Apocyni Veneti Folium: Implications for the
treatment of liver injury. J Ethnopharmacol. 326:1179192024.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Li W, Hao J, Zhang L, Cheng Z, Deng X and
Shu G: Astragalin reduces hexokinase 2 through increasing miR-125b
to inhibit the proliferation of hepatocellular carcinoma cells in
vitro and in vivo. J Agric Food Chem. 65:5961–5972. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hong Z, Lu Y, Ran C, Tang P, Huang J, Yang
Y, Duan X and Wu H: The bioactive ingredients in Actinidia
chinensis Planch. Inhibit liver cancer by inducing apoptosis. J
Ethnopharmacol. 281:1145532021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Pirvu L, Stefaniu A, Neagu G, Albu B and
Pintilie L: In vitro cytotoxic and Antiproliferative Activity of
Cydonia oblonga flower petals, leaf and fruit pellet ethanolic
extracts. Docking simulation of the active flavonoids on
anti-apoptotic protein Bcl-2. Open Chemistry. 16:591–604. 2018.
View Article : Google Scholar
|
|
112
|
Kaidash OA, Kostikova VA, Udut EV, Shaykin
VV and Kashapov DR: Extracts of Spiraea hypericifolia L. and
Spiraea crenata L.: The phenolic profile and biological activities.
Plants. 11:27282022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhou K, Xiao S, Cao S, Zhao C, Zhang M and
Fu Y: Improvement of glucolipid metabolism and oxidative stress via
modulating PI3K/Akt pathway in insulin resistance HepG2 cells by
chickpea flavonoids. Food Chem X. 23:1016302024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Murray CJL: The global burden of disease
study at 30 years. Nat Med. 28:2019–2026. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Nadiminti KVG, Sahasrabudhe KD and Liu H:
Menin inhibitors for the treatment of acute myeloid leukemia:
Challenges and opportunities ahead. J Hematol Oncol. 17:1132024.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Lam CS, Peng LW, Yang LS, Chou HWJ, Li CK,
Zuo Z, Koon HK and Cheung YT: Examining patterns of traditional
Chinese medicine use in pediatric oncology: A systematic review,
meta-analysis and data-mining study. J Integr Med. 20:402–415.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Burmistrova O, Quintana J, Díaz JG and
Estévez F: Astragalin heptaacetate-induced cell death in human
leukemia cells is dependent on caspases and activates the MAPK
pathway. Cancer Lett. 309:71–77. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Lee KH, Tagahara K, Suzuki H, Wu RY,
Haruna M, Hall IH, Huang HC, Ito K, Iida T and Lai JS: Antitumor
agents. 49 tricin, kaempferol-3-O-beta-D-glucopyranoside and
(+)-nortrachelogenin, antileukemic principles from Wikstroemia
indica. J Nat Prod. 44:530–535. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Delloye-Bourgeois C and Castellani V:
Hijacking of embryonic programs by neural crest-derived
neuroblastoma: From physiological migration to metastatic
dissemination. Front Mol Neurosci. 12:522019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gatta G, Botta L, Rossi S, Aareleid T,
Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour
B, et al: Childhood cancer survival in Europe 1999–2007: Results of
EUROCARE-5-a population-based study. Lancet Oncol. 15:35–47. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kholodenko IV, Kalinovsky DV, Doronin II,
Deyev SM and Kholodenko RV: Neuroblastoma origin and therapeutic
targets for immunotherapy. J Immunol Res. 2018:73942682018.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Berlanga P, Cañete A and Castel V:
Advances in emerging drugs for the treatment of neuroblastoma.
Expert Opin Emerg Drugs. 22:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Shekarian T and Valsesia-Wittmann S:
Considerations for the development of innovative therapies against
aggressive neuroblastoma: Immunotherapy and Twist1 targeting.
Neuroblastoma-Current State and Recent Updates. Gowda C: InTech;
2017, View Article : Google Scholar
|
|
124
|
Luksch R, Castellani MR, Collini P, De
Bernardi B, Conte M, Gambini C, Gandola L, Garaventa A, Biasoni D,
Podda M, et al: Neuroblastoma (Peripheral neuroblastic tumours).
Crit Rev Oncol Hematol. 107:163–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Lodrini M, Sprüssel A, Astrahantseff K,
Tiburtius D, Konschak R, Lode HN, Fischer M, Keilholz U, Eggert A
and Deubzer HE: Using droplet digital PCR to analyze MYCN and ALK
copy number in plasma from patients with neuroblastoma. Oncotarget.
8:85234–85251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Johnsen JI, Dyberg C, Fransson S and
Wickström M: Molecular mechanisms and therapeutic targets in
neuroblastoma. Pharmacol Res. 131:164–176. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zafar A, Wang W, Liu G, Wang X, Xian W,
McKeon F, Foster J, Zhou J and Zhang R: Molecular targeting
therapies for neuroblastoma: Progress and challenges. Med Res Rev.
41:961–1021. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Chung MJ, Lee S, Park YI, Lee J and Kwon
KH: Neuroprotective effects of phytosterols and flavonoids from
Cirsium setidens and Aster scaber in human brain neuroblastoma
SK-N-SH cells. Life Sci. 148:173–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Chamoli A, Gosavi AS, Shirwadkar UP,
Wangdale KV, Behera SK, Kurrey NK, Kalia K and Mandoli A: Overview
of oral cavity squamous cell carcinoma: Risk factors, mechanisms,
and diagnostics. Oral Oncol. 121:1054512021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S,
Nice EC, Tang J and Huang C: Oral squamous cell carcinomas: State
of the field and emerging directions. Int J Oral Sci. 15:442023.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Katirachi SK, Grønlund MP, Jakobsen KK,
Grønhøj C and von Buchwald C: The prevalence of HPV in oral cavity
squamous cell carcinoma. Viruses. 15:4512023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Li H, Zhang Y, Xu M and Yang D: Current
trends of targeted therapy for oral squamous cell carcinoma. J
Cancer Res Clin Oncol. 148:2169–2186. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Arboleda LPA, de Carvalho GB, Santos-Silva
AR, Fernandes GA, Vartanian JG, Conway DI, Virani S, Brennan P,
Kowalski LP and Curado MP: Squamous cell carcinoma of the oral
cavity, oropharynx, and larynx: A scoping review of treatment
guidelines worldwide. Cancers (Basel). 15:44052023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ma YX, Li XJ, Jin Q, Ji L and Qiao Q:
Application of neoadjuvant immunotherapy in locally advanced
squamous cell carcinoma of head and neck. Chin J Cancer Prev Treat.
31:968–974. 2024.
|
|
135
|
Wang X, Li J, Chen R, Li T and Chen M:
Active ingredients from Chinese medicine for combination cancer
therapy. Int J Biol Sci. 19:3499–3525. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Zhang X, Qiu H, Li C, Cai P and Qi F: The
positive role of traditional Chinese medicine as an adjunctive
therapy for cancer. Biosci Trends. 15:283–298. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Miao K, Liu W, Xu J, Qian Z and Zhang Q:
Harnessing the power of traditional Chinese medicine monomers and
compound prescriptions to boost cancer immunotherapy. Front
Immunol. 14:12772432023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhao S, Xiao S, Wang W, Dong X, Liu X,
Wang Q, Jiang Y and Wu W: Network pharmacology and transcriptomics
reveal the mechanisms of FFBZL in the treatment of oral squamous
cell carcinoma. Front Pharmacol. 15:14055962024. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Sun Y, Cai J, Ding S and Bao S: Network
Pharmacology Was Used to Predict the Active Components and
Prospective Targets of Paeoniae Radix Alba for Treatment in
Endometriosis. Reprod Sci. 30:1103–1117. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Liu WL, Ji MW, Wang YY, Song LN, Jiang Y
and Shao YK: A case report of diffuse large B-cell lymphoma with
brachial plexus nerve injury as the first symptom. J Apoplexy Nerv
Dis. 37:842–844. 2020.
|
|
141
|
Qi RL, Qiu MH, Zhang T, Zhao XZ, He GP,
Mei HW and Wang HQ: Progress in treatment of recurrent/refractory
diffuse large B-cell lymphoma. Chin Clin Oncol. 27:758–763.
2022.
|
|
142
|
Wang Y, Zhu ML, He SY, Chen H and Chen JY:
Astragalin induces apoptosis of DLBCL cell line OCI-LY8. Chin J
Pathophysiol. 37:885–890. 2021.(In Chinese).
|
|
143
|
Lu Y, Wu N, Fang Y, Shaheen N and Wei Y:
An automatic on-line 2,2-diphenyl-1-picrylhydrazyl-high performance
liquid chromatography method for high-throughput screening of
antioxidants from natural products. J Chromatogr A. 1521:100–109.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Hadzi-Petrushev N, Stojchevski R,
Jakimovska A, Stamenkovska M, Josifovska S, Stamatoski A, Sazdova
I, Sopi R, Kamkin A, Gagov H, et al: GLUT5-overexpression-related
tumorigenic implications. Mol Med. 30:1142024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Thompson AM, Iancu CV, Nguyen TTH, Kim D
and Choe J: Inhibition of human GLUT1 and GLUT5 by plant
carbohydrate products; insights into transport specificity. Sci
Rep. 5:128042015. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Ingram DK and Roth GS: Glycolytic
inhibition: An effective strategy for developing calorie
restriction mimetics. Geroscience. 43:1159–1169. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Harikrishnan H, Jantan I, Alagan A and
Haque MA: Modulation of cell signaling pathways by Phyllanthus
amarus and its major constituents: Potential role in the prevention
and treatment of inflammation and cancer. Inflammopharmacology.
28:1–18. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Devanaboyina M, Kaur J, Whiteley E, Lin L,
Einloth K, Morand S, Stanbery L, Hamouda D and Nemunaitis J: NF-κB
signaling in tumor pathways focusing on breast and ovarian cancer.
Oncol Rev. 16:105682022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Adebayo IA, Balogun WG and Arsad H:
Moringa oleifera: An apoptosis inducer in cancer cells. Trop J
Pharm Res. 16:2289–2296. 2017. View Article : Google Scholar
|
|
150
|
Yang F, Li AM, Zhang YW, Ma CM and Zhang
HR: Study on the effect of astragalin on apoptosis of human colon
cancer SW480 cells. Guo Ji Yi Yao Wei Sheng Dao Bao She.
26:3013–3017. 2020.(In Chinese).
|
|
151
|
Karna KK, Choi BR, You JH, Shin YS, Cui
WS, Lee SW, Kim JH, Kim CY, Kim HK and Park JK: The ameliorative
effect of monotropein, astragalin, and spiraeoside on oxidative
stress, endoplasmic reticulum stress, and mitochondrial signaling
pathway in varicocelized rats. BMC Complement Altern Med.
19:3332019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yun W, Dan W, Liu J, Guo X, Li M and He Q:
Investigation of the mechanism of traditional Chinese medicines in
angiogenesis through network pharmacology and data mining. Evid
Based Complement Alternat Med. 2021:55399702021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Riaz A, Rasul A, Hussain G, Zahoor MK,
Jabeen F, Subhani Z, Younis T, Ali M, Sarfraz I and Selamoglu Z:
Astragalin: A bioactive phytochemical with potential therapeutic
activities. Adv Phar Sc. 2018:1–15. 2018.
|
|
154
|
Lee JH, Saxena A and Giaccone G:
Advancements in small cell lung cancer. Semin Cancer Biol.
93:123–128. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Zhou SB and Chen GZ: Research overview and
reflection on the treatment of cancer-related fatigue in lung
cancer by traditional Chinese medicine. Acta Chin Med Pharm.
52:1–4. 2024.(In Chinese).
|
|
156
|
Adelstein DJ, Moon J, Hanna E, Giri PGS,
Mills GM, Wolf GT and Urba SG: Docetaxel, cisplatin, and
fluorouracil induction chemotherapy followed by accelerated
fractionation/concomitant boost radiation and concurrent cisplatin
in patients with advanced squamous cell head and neck cancer: A
Southwest oncology group phase II trial (S0216). Head Neck.
32:221–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Andreyev HJN, Davidson SE, Gillespie C,
Allum WH and Swarbrick E; British Society of Gastroenterology;
Association of Colo-Proctology of Great Britain Ireland;
Association of Upper Gastrointestinal Surgeons; Faculty of Clinical
Oncology Section of the Royal College of Radiologists, : Practice
guidance on the management of acute and chronic gastrointestinal
problems arising as a result of treatment for cancer. Gut.
61:179–192. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Bower JE: The role of neuro-immune
interactions in cancer-related fatigue: Biobehavioral risk factors
and mechanisms. Cancer. 125:353–364. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
de Raaf PJ, Sleijfer S, Lamers CHJ, Jager
A, Gratama JW and van der Rijt CCD: Inflammation and fatigue
dimensions in advanced cancer patients and cancer survivors: an
explorative study. Cancer. 118:6005–6011. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wen YL, Li WY, Zhang N, Su RZ, Xia JR, Li
LF and Tian Y: The inhibitory effect of astragalin on escherichia
coli and its mechanism. J Yunnan Agricultural University.
37:471–477. 2022.
|
|
161
|
Oraibi AI, Dawood AH, Trabelsi G, Mahamat
OB, Chekir-Ghedira L and Kilani-Jaziri S: Antioxidant activity and
selective cytotoxicity in HCT-116 and WI-38 cell lines of LC-MS/MS
profiled extract from Capparis spinosa L. Front Chem.
13:15401742025. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Yang X, Ma B, Zhang Q, Wu X, Gu G, Li J,
Sun J, Tang B, Zhu J, Qia H and Ying H: Comparative
pharmacokinetics with single substances and Semen Cuscutae extract
after oral administration and intravenous administration Semen
Cuscutae extract and single hyperoside and astragalin to rats. Anal
Methods. 6:72502014. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Adamu UM, Renggasamy R, Stanslas J, Razis
AF, Fauzi F, Mulyani SW and Ramasamy R: In-silico prediction
analysis of polyphenolic contents of ethanolic extract of moringa
oleifera leaves. Malays J Med Health Sci. 19:9–15. 2023.
|
|
164
|
Liu J, Zou S, Liu W, Li J, Wang H, Hao J,
He J, Gao X, Liu E and Chang Y: An Established HPLC-MS/MS method
for evaluation of the influence of salt processing on
pharmacokinetics of six compounds in cuscutae semen. Molecules.
24:25022019. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Choung WJ, Hwang SH, Ko DS, Kim SB, Kim
SH, Jeon SH, Choi HD, Lim SS and Shim JH: Enzymatic synthesis of a
novel Kaempferol-3-O-β-d-glucopyranosyl-(1→4)-O-α-d-glucopyranoside
using cyclodextrin glucanotransferase and its inhibitory effects on
aldose reductase, inflammation, and oxidative stress. J Agric Food
Chem. 65:2760–2767. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Ren C, Xi Z, Xian B, Chen C, Huang X,
Jiang H, Chen J, Peng C and Pei J: Identification and
characterization of CtUGT3 as the key player of astragalin
biosynthesis in Carthamus Tinctorius L. J Agric Food Chem.
71:16221–16232. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Pei J, Dong P, Wu T, Zhao L, Fang X, Cao
F, Tang F and Yue Y: Metabolic engineering of Escherichia Coli for
astragalin biosynthesis. J Agric Food Chem. 64:7966–7972. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Zhang Y, Lei X, Xu H, Liu G, Wang Y, Sun
H, Geng F and Zhang N: Tissue distribution of total flavonoids
extracts of drynariae rhizoma in young and old rats by UPLC-MS/MS
determination. J Anal Methods Chem. 2022:1–30. 2022. View Article : Google Scholar
|
|
169
|
Li N, Lv T, Pan J, Liu C, Sun J, Lan Y,
Wang A, Li Y, Wang Y and Lu Y: Comparative tissue distribution of 6
major polyphenolic compounds in normal and myocardial ischemia
model rats after oral administration of the Polygonum
orientale L. Extract. Nat Prod Commun.
15:1934578X209294472020.
|
|
170
|
He B, Bai X, Tan Y, Xie W, Feng Y and Yang
GY: Glycosyltransferases: Mining, engineering and applications in
biosynthesis of glycosylated plant natural products. Synth Syst
Biotechnol. 7:602–620. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Han YM, Koh J, Kim JH, Lee J, Im JP and
Kim JS: Astragalin inhibits nuclear Factor-κB signaling in human
colonic epithelial cells and attenuates experimental colitis in
mice. Falk Symp. 15:100–108. 2021.
|
